EMA Withdrawn: Absimky (ustekinumab) — Accord Healthcare S.L.U.

View source ↗

Summary

EMA has withdrawn Absimky (ustekinumab) from Accord Healthcare S.L.U., affecting its use for Crohn disease and ulcerative colitis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Crohn Disease
• Ulcerative Colitis

Drugs mentioned

• Absimky (ustekinumab)

Snippet

Status: Withdrawn. Therapeutic area: Crohn Disease;Colitis, Ulcerative. MAH: Accord Healthcare S.L.U.. Decision date: 20/06/2025